Advertisement
Advertisement
NVCT
Nuvectis Pharma, Inc. Common Stock
11.65
USDSponsored
+1.33
+12.89%
May 08, 16:00 UTC -4
Closed
After-Market
11.55
-0.10
-0.86%
NVCT Earnings Reports
Positive Surprise Ratio
NVCT beat 5 of 16 last estimates.
31%
Next Report
Tomorrow
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.31
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/+14.81%
Nuvectis Pharma, Inc. Common Stock earnings per share and revenue
On Feb 11, 2026, NVCT reported earnings of -0.31 USD per share (EPS) for Q4 25, missing the estimate of -0.30 USD, resulting in a -2.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.46% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.31 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
What were Nuvectis Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Nuvectis Pharma, Inc. Common Stock reported EPS of -$0.31, missing estimates by -2.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Nuvectis Pharma, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 0.46%, changed from $8.74 before the earnings release to $8.78 the day after.
When is Nuvectis Pharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Nuvectis Pharma, Inc. Common Stock's next earnings report?
Based on --
analysts, Nuvectis Pharma, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement